Jump to main content
Jump to site search

Issue 6, 2018
Previous Article Next Article

Self-stabilized, hydrophobic or PEGylated paclitaxel polymer prodrug nanoparticles for cancer therapy

Author affiliations

Abstract

Facile derivatization of paclitaxel (Ptx) and subsequent “drug-initiated” synthesis of well-defined Ptx-polymer prodrugs was performed from nitroxide-mediated polymerization or reversible addition–fragmentation chain transfer polymerization. Short polyisoprene (Mn = 2640–4310 g mol−1, Đ ∼ 1.1) or poly[(oligo(ethylene glycol) methyl ether methacrylate)] (Mn = 5580–7530 g mol−1, Đ ∼ 1.2) chains were grown from Ptx in a controlled fashion and enabled, for the first time, the formation of either self-stabilized, all-hydrophobic Ptx-polymer prodrug nanoparticles or their PEGylated counterparts. They exhibited average diameters in the 110–235 nm range, great colloidal stability in PBS and cell culture medium, high drug loadings (up to 32 wt%) and cytotoxicity similar to that of the parent drug on three different cancer cell lines (A549, L1210 and MCF-7). This versatile approach is expected to provide more potent anticancer nanocarriers and rejuvenate the development of Ptx-based nanomedicines.

Graphical abstract: Self-stabilized, hydrophobic or PEGylated paclitaxel polymer prodrug nanoparticles for cancer therapy

Back to tab navigation

Supplementary files

Publication details

The article was received on 15 Nov 2017, accepted on 22 Dec 2017 and first published on 10 Jan 2018


Article type: Paper
DOI: 10.1039/C7PY01918A
Citation: Polym. Chem., 2018,9, 687-698
  •   Request permissions

    Self-stabilized, hydrophobic or PEGylated paclitaxel polymer prodrug nanoparticles for cancer therapy

    Y. Bao, E. Guégain, J. Mougin and J. Nicolas, Polym. Chem., 2018, 9, 687
    DOI: 10.1039/C7PY01918A

Search articles by author

Spotlight

Advertisements